PharmaFocus Today – Page 6 – media

Changes in the order of BTK inhibitors

Over the past decade, the BTK inhibitor market has continued to explode. Since ibrutinib was approved for the treatment of chronic lymphocytic leukemia in 2013, BTK inhibitors have been advancing rapidly, almost dominating the field of hematological tumors, and the market size has exceeded 10 billion US dollars. Of course, with more and more players entering the market, the BTK inhibitor market has also become undercurrent. Ibrutinib is on the decline, and new generation forces such as Calquence, Zebutinib and Pirtobrutinib are on the rise, and more players will enter the market in the future. The emergence of more BTK inhibitors will provide patients with new options for controlling disease progression, but will also bring a new problem: how to combine and how to sort? This still needs pharmaceutical companies to find the answer through exploration. At this year’s ASH Annual Meeting, some pharmaceutical companies brought some new answers to ...
- Source: drugdu
- 55
- December 13, 2024
RSV vaccine clinical trials for infants have been suspended, and safety issues have been foreshadowed

For the increasingly bloated RSV vaccine market, analysts generally conclude that the two RSV vaccines from Pfizer and GSK will dominate the market, while Moderna’s newly launched mRNA vaccine mRNA-1345 (i.e. mResvia) will not occupy much market share this winter due to a variety of reasons such as insufficient commercial preparation. However, now it seems that Moderna may face a worse situation in the future. In the briefing document released by the FDA on December 10, a more unfavorable information for Moderna was revealed: mRNA-1345 and mRNA-1365 may even aggravate RSV virus infection, repeating the mistake of more than 60 years ago that “Pfizer vaccine not only did not alleviate the symptoms of infection, but aggravated the condition of infants and caused death.” Affected by this news, Moderna’s stock price also fell 9% at the close of the market on the 10th. ▍Safety issues that were foreshadowed In July of ...
- Source: drugdu
- 51
- December 13, 2024
The Medical Insurance Bureau named and rectified high-priced Chinese patent medicines

Chinese patent medicines are the concentrated essence of traditional Chinese medicine culture. Compared with Chinese medicine decoctions, they do not need to be decocted and can be used directly. At the same time, they are small in size, easy to carry and store, especially convenient for patients with critical illnesses and patients who need long-term treatment. However, its prices are “ups and downs” and “very different”. Recently, the National Medical Insurance Bureau guided the Hubei Provincial Medical Insurance Bureau to take the lead in carrying out the national alliance procurement of Chinese patent medicines, which will reduce the price of Chinese patent medicines, compress the price difference, and form a more transparent and benign competition market, so that the general public can benefit. ▍What is Chinese patent medicine? Chinese patent medicine is a preparation with certain specifications and dosage forms that can be directly used for the prevention and treatment ...
- Source: drugdu
- 47
- December 13, 2024
Innovent Biologics’ “IL-4Rα/TSLP Dual Antibody” Applies for Clinical Trial in China

On December 7, according to the official website of CDE, the clinical trial application of Innovent Biologics’ Class 1 new drug IBI3002 was accepted. According to public information, IBI3002 is a FIC bispecific antibody targeting IL-4Rα and TSLP. Asthma is a heterogeneous disease mediated by a variety of immune cells, cytokines and inflammatory mediators, affecting people of all ages, characterized by a variety of symptoms such as wheezing, shortness of breath, cough and chest tightness, with hundreds of millions of patients worldwide. Drug treatment is one of the important means to relieve and control asthma. The IL-4 receptor mediates the IL-4 signaling pathway (type 1 and type 2) and the IL-13 signaling pathway (type 2), and both cytokine signaling pathways play a key role in the pathophysiology of type 2 inflammatory diseases. TSLP is an epithelial cell-derived alarmin cytokine that triggers type 2 and non-type 2 inflammation in asthma. According ...
- Source: drugdu
- 46
- December 13, 2024
The world’s first valve disruptor plans IPO

Australian innovative structured heart disease listed company Anteris Technologies (ASX: AVR) officially announced today that it has launched its initial public offering (IPO) in the United States, planning to issue 14.8 million shares at a price of $6.78 per share to raise $100 million. According to the proposed price, the market value of Anteris Technologies will reach $244 million (approximately RMB 1.77 billion). The funds raised will fully promote the research and development process of its innovative DurAVR transcatheter heart valve technology. This product is the world’s first integrated leaflet aortic valve using a single piece of biological tissue engineering, resulting in lower mechanical stress, optimal hemodynamics, and the ability to mimic the performance of healthy human aortic valves. The company calls it the TAVR that shapes the future and is highly regarded in the medical community. The IPO plans to issue 14.8 million ordinary shares and grant underwriters the ...
- Source: drugdu
- 58
- December 12, 2024
Fujifilm, Shining Oriental Digestive Endoscopy Academic Conference

01. Conference Introduction The 5th Oriental Digestive Endoscopy Academic Conference, hosted by the Shanghai Medical Association and the Digestive Endoscopy Branch of the Shanghai Medical Association, and co organized by the First Affiliated Hospital of Naval Medical University, Huashan Hospital affiliated with Fudan University, and Zhongshan Hospital affiliated with Fudan University, was successfully held in Shanghai from November 22nd to 24th. This conference, with the concept of “integrating innovation and pursuing excellence”, has gathered more than a thousand experts and scholars in the field of digestion. Led by endoscopy in the diagnosis and treatment of major digestive diseases, it adopts a multidisciplinary and multi forum joint meeting to jointly explore and share clinical experience and the latest research results in the field of digestion. It can be said that it is a perfect combination and complement each other. 02. Various highlights of the booth As an important event in the ...
- Source: drugdu
- 53
- December 12, 2024
Recently, the traditional Chinese medicine industry has been heavily involved in mergers and acquisitions, with multiple companies “crossing boundaries” to layout biochemical innovative drugs

This year, traditional Chinese medicine companies have been intensively involved in mergers and acquisitions. Since August, listed Chinese medicine companies such as Lingrui Pharmaceutical, Kangyuan Pharmaceutical, Pianzaihuang, and CR Sanjiu have announced their merger and acquisition plans. At the same time, the recent establishment of investment funds by Yunnan Baiyao and Pianzaihuang is also considered a prelude to outward mergers and acquisitions. Li Zhong, a senior marketing expert in the pharmaceutical industry, stated in an interview with 21st Century Business Herald that the integration of the entire traditional Chinese medicine industry is inevitable and belongs to the national strategic direction. Large traditional Chinese medicine enterprises may increase their integration efforts, and the industry will present a stronger and stronger force. Traditional Chinese medicine enterprises with well-known brands, good products, good teams, and good research and development will develop rapidly. At the same time, some small enterprises will naturally be integrated, ...
- Source: drugdu
- 50
- December 12, 2024
The first domestic drug for treating Duchenne muscular dystrophy, Angelide ® Approved for listing

On December 11, 2024, Shufang Medicine announced the announcement of Anjiali ® (Common name: Vamorolone Oral Suspension, Vamorolone); Specification: 40mg/mL, 100mL/bottle) has recently been approved by the National Medical Products Administration (NMPA) of China for the treatment of Duchenne muscular dystrophy (DMD) patients aged four years and above. Angali ® It is the first domestically approved treatment drug for Duchenne muscular dystrophy. Angali ® Previously, it was included in the breakthrough treatment drug and priority review procedures by the Drug Evaluation Center of the National Medical Products Administration.Duchenne muscular dystrophy is a rare neuromuscular disease that often occurs in childhood, and there is a huge unmet medical need in this field. Angali ® It is the first DMD treatment drug that has been fully approved in both the United States and the European Union. Its receptor that binds to glucocorticoids is the same, but its downstream activity is altered. Compared ...
- Source: drugdu
- 48
- December 12, 2024
GLP-1 fired a shot at the AD market?

As we all know, Alzheimer’s disease is still one of the most difficult diseases in the world. The core is that the medical community still knows very little about its pathogenesis. There are currently two mainstream hypotheses about the mechanism of Alzheimer’s disease: One is the Aβ hypothesis, that is, the overexpression of β-amyloid protein (Aβ) aggregates into amyloid plaques; the other is the Tau protein hypothesis, that is, the neurofibrillary tangles formed by the misfolding of Tau protein after excessive phosphorylation. Regardless of which hypothesis, countless pharmaceutical companies have failed frequently, including the Aβ hypothesis that is most recognized by pharmaceutical companies. According to this hypothesis, the more completely the drug clears the amyloid plaques in the patient’s brain, the more beneficial it is for controlling the development of the disease. Donanemab and lecanemab, which have been approved, are the same, but the mechanisms are different. How much benefit ...
- Source: drugdu
- 57
- December 11, 2024
China’s gene sequencing industry survives the darkest moment

When it comes to the major issue of China’s gene sequencing industry, the Biosafety Act is an unavoidable topic. At the beginning of the year, in the draft version of the Biosafety Act submitted by members of the U.S. House of Representatives, domestic companies such as WuXi AppTec, BGI, and BGI were mentioned; a similar draft bill was recently proposed by the U.S. Senate. If these bills are passed, medical institutions funded by the U.S. government will be restricted from using the products and technologies of the mentioned companies. Therefore, the Biosafety Act inevitably caused excessive panic in the domestic capital market, causing some companies to oversell. Since the “924 market”, the Science and Technology Innovation 50 has been a weather vane, with a cumulative increase of nearly 20%. Although BGI is a component of the Science and Technology Innovation 50, its stock price has fallen by nearly 40% since ...
- Source: drugdu
- 56
- December 11, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.